Last 12 months
Inside the activity.
1 purchase rows · 18 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 1 | 7 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2020 Filed Nov 6, 2020 21:38 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-057297 · doc4.xml · derivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,234 Underlying: Common Stock · 50,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:38 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 50,000 | $26.00 | $1,300,000.00 |
DisclosureSEC source: 0001209191-20-057297 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:38 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 50,000 | $6.83 | $341,500.00 |
DisclosureSEC source: 0001209191-20-057297 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · derivative · entry 5 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 156 | $24.55 | $3,829.80 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,679 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,459 | $24.19 | $132,053.21 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,835 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.53 to $24.49, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 15, 2020 at each separate price. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:58 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-055196 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:14 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-054440 · doc4.xml · derivative · entry 4 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,234 Underlying: Common Stock · 5,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:14 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 5,000 | $21.83 | $109,150.00 |
DisclosureSEC source: 0001209191-20-054440 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:14 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001209191-20-054440 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:15 UTC |
Crowley John FDirector
|
GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $18.83 | $0.00 |
DisclosureSEC source: 0001209191-20-053583 · doc4.xml · derivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: This option shall vest as follows: 33 1/3% shares shall vest on October 2, 2021, and the remaining shares shall vest 66 2/3% in 12 equal quarterly installments. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,615 | $21.04 | $118,139.60 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,294 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:55 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-050945 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:15 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-049379 · doc4.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,234 Underlying: Common Stock · 5,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:15 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 5,000 | $21.83 | $109,150.00 |
DisclosureSEC source: 0001209191-20-049379 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:15 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001209191-20-049379 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,615 | $21.00 | $117,915.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,909 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 16:13 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-047713 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:29 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0000899243-20-021784 · doc4.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,234 Underlying: Common Stock · 5,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:29 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 5,000 | $21.83 | $109,150.00 |
DisclosureSEC source: 0000899243-20-021784 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 23:29 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0000899243-20-021784 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,615 | $22.70 | $127,460.50 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,524 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:18 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-042820 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 857 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:10 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-040251 · doc4.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,234 Underlying: Common Stock · 5,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:10 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 5,000 | $21.83 | $109,150.00 |
DisclosureSEC source: 0001209191-20-040251 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:10 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001209191-20-040251 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:44 UTC |
FORMELA JEAN FRANCOISDirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037964 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:44 UTC |
DORSA CAROLINEDirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037961 · doc4.xml · derivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:45 UTC |
GOODMAN JESSEDirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037967 · doc4.xml · derivative · entry 1 GOODMAN JESSE · CIK 0001756929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:13 UTC |
Cohen Fred EDirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037992 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:47 UTC |
Verwiel FrankDirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037971 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:46 UTC |
KARSEN PERRY ADirector
|
GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037970 · doc4.xml · derivative · entry 1 KARSEN PERRY A · CIK 0001260573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · derivative · entry 4 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,615 | $21.00 | $117,915.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,282 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 17:00 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-037647 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:18 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-034724 · doc4.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,234 Underlying: Common Stock · 5,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:18 UTC |
LEONARD JOHN MDirector · President and CEO
|
SaleCommon Stock | 5,000 | $21.83 | $109,150.00 |
DisclosureSEC source: 0001209191-20-034724 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,352 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:18 UTC |
LEONARD JOHN MDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001209191-20-034724 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · derivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,117 Underlying: Common Stock · 10,000 shares Expires 2026-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC |
Rivera Jose EEVP, General Counsel
|
SaleCommon Stock | 5,615 | $21.21 | $119,094.15 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · nonDerivative · entry 2 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,107 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F1 · balance_after: 262,210 of these shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. Read SEC document |
| May 26, 2020 Filed May 28, 2020 17:23 UTC |
Rivera Jose EEVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $6.83 | $68,300.00 |
DisclosureSEC source: 0001209191-20-032648 · doc4.xml · nonDerivative · entry 1 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 262,210 of these shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:49 UTC |
Lebwohl DavidEVP, Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001209191-20-027165 · doc4.xml · derivative · entry 1 Lebwohl David · CIK 0001810882 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-04-30 F1 · derivative.exercise_date: This option was granted on May 1, 2020 with respect to 200,000 shares of Common Stock, with 25% vesting on May 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:27 UTC |
SCHIERMEIER ANDREWEVP, Chief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006973 · doc4.xml · derivative · entry 3 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2030-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:30 UTC |
Sepp-Lorenzino LauraEVP, Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006978 · doc4.xml · derivative · entry 1 Sepp-Lorenzino Laura · CIK 0001777421 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:28 UTC |
Rivera Jose EEVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006976 · doc4.xml · derivative · entry 3 Rivera Jose E · CIK 0001671870 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:30 UTC |
LEONARD JOHN MDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006979 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 340,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:28 UTC |
Goddard GlennEVP, Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006975 · doc4.xml · derivative · entry 1 Goddard Glenn · CIK 0001581992 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.